Tricuspid regurgitation (TR) is a common cardiac valve disease for which conventional medical therapy offers limited benefits and surgical intervention carries significant risks. With advancements in transcatheter tricuspid valve intervention (TTVI) techniques, it has emerged as an important treatment option for patients with severe TR who are at high surgical risk. Based on Chinese Expert Consensus on Transcatheter Tricuspid Valve Intervention Therapy, this article provides an in-depth discussion on key aspects including TR pathological classification and prognosis, indication criteria, treatment strategies, selection of TTVI devices, study endpoints, and multidisciplinary team building. The aim is to elucidate the content of the consensus, enhance readers’ systematic understanding of TTVI, and promote the safe and standardized adoption of this technology in China.
Tricuspid regurgitation (TR) is a common but often neglected valvular heart disease. Growing evidence has highlighted its association with poor prognosis and the complexity of its management. In recent years, transcatheter tricuspid valve intervention (TTVI) has emerged as a promising minimally invasive approach, with accumulating evidence supporting its safety and short-term efficacy. Transcatheter approaches offer a new therapeutic alternative for high-risk TR patients, but the clinical indications for TTVI are still being refined. This review summarizes recent advancements in TTVI technology, compares the indications for surgical and transcatheter therapies, and discusses the critical role of right heart function and pulmonary circulation in therapeutic decision-making.
Tricuspid regurgitation (TR) is a clinically prevalent valvular heart disease with an age-dependent increase in incidence. Patients with symptomatic severe TR are confronted with limited efficacy of medical treatment and high risks of surgical intervention. In recent years, transcatheter tricuspid valve replacement has rapidly evolved as a novel therapeutic strategy to address the challenge. This article systematically reviews the design features and clinical studies of transcatheter tricuspid valve replacement devices globally, providing valuable insights and evidence for expanding clinical approaches in the treatment of the patients with TR.